2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101390B
    Niguldipine 102993-22-6 98%
    Niguldipine is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine on myocardial metabolism is not significant.
    Niguldipine
  • HY-101390D
    (R)-Niguldipine 120054-86-6
    (R)-Niguldipine, a R-epimer of Niguldipine (HY-101390B), is a calcium channel antagonist. (R)-Niguldipine exerts a vasodilatory effect by blocking calcium channels and reducing the transmembrane influx of calcium ions. (R)-Niguldipine can inhibit U-46619 (HY-108566)-induced coronary artery contraction in guinea pig Langendorff hearts (pID50 of 9.93), has high affinity for calcium channel binding sites on guinea pig skeletal muscle membranes (Ki of 8.10), and lowers blood pressure in spontaneously hypertensive rats (pED30 of 5.55). (R)-Niguldipine can improve cardiovascular diseases such as hypertension, angina pectoris, and arrhythmias.
    (R)-Niguldipine
  • HY-101607A
    KT-362 free acid 93392-97-3 98%
    KT-362 free acid is an intracellular calcium antagonist with antiarrhythmic and vasodilatory effects. KT-362 free acid shows an antagonistic effect against norepinephrine (NE) induced vasoconstriction response, achieved by reducing inositol phospholipid hydrolysis, thereby reducing intracellular calcium mobilization. KT-362 free acid can be used to study the contraction and relaxation mechanisms of vascular smooth muscle, especially in exploring the role of intracellular calcium mobilization and inositol phospholipid hydrolysis in vascular contraction.
    KT-362 free acid
  • HY-101617A
    Droxicainide hydrochloride 149572-05-4 98%
    Droxicainide hydrochloride is an antiarrhythmic agent.
    Droxicainide hydrochloride
  • HY-10163S2
    Dabigatran-13C6 1210608-88-0 98%
    Dabigatran-13C6 is the 13C labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-13C6
  • HY-10163S3
    Dabigatran-13C,d3 98%
    Dabigatran-13C,d3 is the 13C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-13C,d3
  • HY-10163S5
    Dabigatran-d7 2512224-24-5 98%
    Dabigatran-d7 (BIBR 953-d7; BIBR 953ZW-d7) is the deuterium labeled Dabigatran (HY-10163). Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-d7
  • HY-101682B
    (R)-SCH 42495 156792-25-5 98%
    (R)-SCH 42495 is the less active enantiomer of SCH 42495. SCH 42495 is an orally active neutral metalloendopeptidase (NEP) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester proagent of SCH 42354.
    (R)-SCH 42495
  • HY-101685A
    Iganidipine dihydrochloride 117241-46-0 98%
    Iganidipine dihydrochloride is a Ca2+ antagonist.
    Iganidipine dihydrochloride
  • HY-101700A
    LCB 2853 sodium 141335-11-7 98%
    LCB 2853 sodium is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist. LCB 2853 sodium exhibits anti-aggregant and anti-vasospastic effects. LCB 2853 sodium can be used for the research of cardiovascular disease, such as hypertension.
    LCB 2853 sodium
  • HY-101723R
    Modecainide (Standard) 81329-71-7
    Modecainide (Standard) is the analytical standard of Modecainide. This product is intended for research and analytical applications. Modecainide is a major metabolite of Encainide, which is an antiarrhythmic agent.
    Modecainide (Standard)
  • HY-101809A
    CNS 5161 160754-76-7 98%
    CNS-5161 is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
    CNS 5161
  • HY-103045A
    CMPD101 hydrochloride 1941168-71-3 98%
    CMPD101 hydrochloride is a novel membrane-permeable, small-molecule inhibitor of both GRK2 and GRK3 with IC50s of 18 nM and 5.4 nM, respectively. CMPD101 hydrochloride also inhibits Rho-associated kinase 2 (ROCK-2) and PKCα (IC50s =1.4 μM and 8.1 μM, respectively).
    CMPD101 hydrochloride
  • HY-103160B
    EHNA 51350-19-7 98%
    EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects.
    EHNA
  • HY-103185A
    CCPA hemihydrate 1217443-91-8 98%
    CCPA (2-Chloro-N6-cyclopentyladenosine) hemihydrate a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA hemihydrate inhibits adenylate cyclase with an IC50 of 33 nM. CCPA hemihydrate exhibits anti-seizure and cardiacprotective activity. CCPA hemihydrate can be used for the research of seizure and myocardial infarction.
    CCPA hemihydrate
  • HY-103202A
    SNAP5089 157066-76-7 98%
    SNAP5089 is a selective α1A-adrenoceptor antagonist with over 1700-fold selectivity for the α1A subtype, which may have implications for the treatment of hypertension and benign prostatic hypertrophy. SNAP5089 demonstrates significant receptor affinity compared to other clinical drugs, emphasizing its potential therapeutic advantages. SNAP5089's high affinity aligns with its suitability for conditions where precise α1A modulation is desirable.
    SNAP5089
  • HY-103214A
    Bucindolol hydrochloride 70369-47-0 98%
    Bucindolol hydrochloride is a β-adrenergic receptor antagonist with activity in preventing new-onset atrial fibrillation. Bucindolol hydrochloride can reduce heart rate and the occurrence of bradycardia in patients with heart failure and atrial fibrillation.
    Bucindolol hydrochloride
  • HY-103247B
    EMD-66684 potassium salt 187683-79-0 98%
    EMD-66684 potassium salt is a non-peptide angiotensin II receptor antagonist that demonstrates significant antihypertensive effects in spontaneously hypertensive rats. EMD-66684 potassium salt exhibits nanomolar affinity for angiotensin II receptors, comparable to losartan in potency. EMD-66684 potassium salt shows increased activity when modified with acetamides, leading to superior blood pressure reduction.
    EMD-66684 potassium salt
  • HY-105011A
    YM-358 hydrate potassium 161800-08-4 98%
    YM-358 hydrate potassium is an orally active angiotensin II type 1 (AT1)-receptor antagonist. YM-358 hydrate potassium can decrease cardiac volume overload. YM-358 hydrate potassium can be used for the research of cardiovascular disease, such as hypertension.
    YM-358 hydrate potassium
  • HY-105064A
    Zoniporide mesylate 249296-45-5 98%
    Zoniporide mesylate (CP-597396 mesylate) is a potent and selective NHE-1 inhibitor with cardioprotective activity. Zoniporide inhibits 22Na+ uptake by human NHE-1-expressing fibroblasts in a concentration-dependent manner (IC50=14 nM). Zoniporide inhibits platelet swelling in vitro with an IC50 of 0.059 μM. Zoniporide can be used in the study of cardiovascular disease.
    Zoniporide mesylate
Cat. No. Product Name / Synonyms Application Reactivity